Clinical Trial Update: Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating the combination of oral decitabine and ivosidenib as first-line therapy for older or unfit adults with gene-mutated acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (oral) (decitabine)
• Ivosidenib (ivosidenib)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Status: NOT_YET_RECRUITING